Biodefense: Complementary Roles within DHHS

CDC

- Surveillance and Detection
- Train Local Response Teams
- Maintain Vaccine/Antimicrobial Stockpiles

NIH

- Conduct Basic Research
- Develop Medical Interventions
- Develop Research Infrastructure

FDA

- Regulatory Approval
  - Vaccines
  - Therapeutics
  - Diagnostics

OPHEP

- HHS-Wide Coordination of Emergency Preparedness Activities

NIH Biodefense Research Funding, FY 2000-2006



*Does not include $47.4M in HHS FYs 2005 and 2006 for nuclear/radiobiology defense research and $50M in FY 2006 for chemical defense research.


NIAID
BIODEFENSE
Preparing Through Research
NIAID Strategic Plan for Biodefense Research


NIAID
BIODEFENSE
Preparing Through Research
NIAID Biodefense Research Agenda for CDC Category A Agents


NIAID
BIODEFENSE
Preparing Through Research
NIAID Biodefense Research Agenda for Category B and C Priority Pathogens
January 2003

NIAID
BIODEFENSE
Preparing Through Research
NIAID Biodefense Research Agenda for CDC Category A Agents
Progress Report
August 2003


NIAID
BIODEFENSE
Preparing Through Research
NIAID Biodefense Research Agenda for Category B and C Priority Pathogens
Progress Report
June 2004
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases


Therapeutics
Vaccines
Diagnostics
Biodefense Research Priorities
Basic Research (including Genomics)
Expansion of Research Capacity

Expansion of Biodefense Research Capacity



Basic Research in Biodefense: Progress and Priorities



Countermeasure Development: Key Achievements

Smallpox

- More than 300 million doses of smallpox vaccine now available
- "Next-generation" vaccine (MVA) in advanced testing
- Antiviral drug development, e.g. oral cidofovir

Anthrax

- New vaccine (rPA) tested and procured under Project Bioshield
- Development of novel antitoxins, e.g. monoclonal/polyclonal antibodies

Countermeasure Development: Key Achievements (continued)

Ebola

- Vaccine in human trials at NIAID Vaccine Research Center

Botulinum Toxin

- Development of vaccine and monoclonal/polyclonal antibodies

Influenza

- Development of vaccines against potential pandemic strains

Countermeasure Development: A Changing Paradigm



San Francisco Chronicle

NORTHERN CALIFORNIA'S LARGEST NEWSPAPER

FEBRUARY 18, 2002

Bioterror Funds a Boon for Public Health

Experts say research will apply to fighting infectious diseases

Global Examples of Emerging and Re-Emerging Infectious Diseases